Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
164.24
+0.83 (0.51%)
Aug 10, 2026, 2:16 PM EDT - Market open
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $213.13. The average 1-year stock price forecast is 29.77% higher than the current stock price, while the lowest is $190 (+15.68%) and the highest is $249 (+51.61%).
Price Target: $213.13 (+29.77%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 19 | 20 | 21 | 19 | 19 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 27 | 28 | 29 | 27 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $185 → $217 | Buy | Maintains | $185 → $217 | +32.12% | Aug 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $185 → $194 | Buy | Maintains | $185 → $194 | +18.12% | Aug 3, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $200 → $210 | Buy | Reiterates | $200 → $210 | +27.86% | Aug 3, 2026 |
| Citi | Citi | Buy Maintains $246 → $249 | Buy | Maintains | $246 → $249 | +51.61% | Aug 3, 2026 |
| Truist Financial | Truist Financial | Buy Reiterates $213 | Buy | Reiterates | $213 | +29.69% | Aug 3, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 2.86B
Increased by 36.39%
Revenue Next Year
4.57B
from 3.90B
Increased by 17.09%
EPS This Year
10.17
from 6.39
Increased by 59.15%
EPS Next Year
12.17
from 10.17
Increased by 19.70%
EPS and Forward PE are based on non-GAAP adjusted numbers.